<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MECLOCYCLINE SULFOSALICYLATE</span><br/>(me-kloe-sye'kleen)<br/><span class="topboxtradename">Meclan<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">tetracycline</span><br/><b>Prototype: </b>Tetracycline<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1% cream</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic derivative of oxytetracycline. Antibacterial action appears to be related to ability to suppress growth of susceptible
         organisms.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Suppresses growth of <i>Propionibacterium acnes,</i> an anaerobic organism in sebaceous glands and follicles. Inactive against viruses and fungi.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Inflammatory acne vulgaris.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tetracyclines or any ingredients in the formulation (e.g., formaldehyde). Safety during pregnancy (category
         B), lactation, or in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Inflammatory Acne Vulgaris</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply to affected areas b.i.d., a.m. and p.m.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply cream generously morning and evening over affected skin areas.</li>
<li>Use less frequent applications depending on patient's response.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Skin irritation; stinging, burning sensation; temporary yellow staining of skin around hair follicles (with excessive applications),
      superinfections. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Not absorbed systemically in measurable amounts. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor patients with kidney or liver dysfunction carefully since significant percutaneous absorption may result with prolonged
            use.
         </li>
<li>Monitor for S&amp;S of superinfection (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Keep follow-up appointments. Overuse of tetracycline preparations can result in overgrowth of nonsusceptible organisms.</li>
<li>Be aware that excessive applications may cause temporary staining around hair roots and also can stain fabrics.</li>
<li>Avoid use near or in eyes, ears, nose, mouth, or other mucous membranes.</li>
<li>Notify physician if noticeable improvement has not occurred by 6Â–8 wk. Maximum benefit may not be apparent for <img src="../images/special/greaterorequal.gif"/>12
            wk.
         </li>
<li>Treated skin areas will be fluorescent under ultraviolet light.</li>
<li>Take care using abrasive or medicated soaps and cleaners, other topical acne preparations, alcohol-containing preparations
            (e.g., after-shave astringents, lotions), "cover-up" medications, peeling agents (e.g., benzoyl peroxide, resorcinol,
            sulfur, salicylic acid, tretinoin). Possible cumulative drying or irritant effects can occur. Use such preparations with caution
            and only under medical guidance.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>